Amplitude Vascular Systems
Amplitude Vascular Systems is a pre-commercial medical device company developing the Pulse IVL hydraulic intravascular lithotripsy system to fracture arterial calcium in peripheral, coronary, and carotid vessels for hospitals and interventional cardiologists; acquired by Stryker in May 2026 for up to $835 million.
- Company typePrivate
- Founded2017
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Amplitude Vascular Systems does
Amplitude Vascular Systems (AVS), founded in 2017 and headquartered in Waltham, Massachusetts, is a venture-backed medical device company developing the Pulse IVL™ System — a hydraulic intravascular lithotripsy (IVL) platform for treating severely calcified arterial disease. The system converts pressurized hospital-grade CO2 into high-frequency (15 pulses/second) hydraulic pressure waves of approximately 50 atm peak pressure that travel through the catheter shaft to a non-compliant balloon at the lesion site, producing uniform, multi-directional calcium fractures along the entire balloon length while simultaneously post-dilating the vessel. Unlike competing IVL catheters that rely on stiff electrical emitter elements, AVS's emitter-free catheter architecture is engineered for lower crossing profiles and improved deliverability, with safety features including a 45-second blood-flow lock-out and automatic shut-off on balloon rupture, and a single amplifier case supporting up to 5,000 pulses.
The platform is being clinically evaluated through the POWER PAD I first-in-human study (9 patients, 0 Grade D dissections, post-procedure stenosis reduced from 77% to 21%) and the FDA-approved POWER PAD II pivotal IDE trial enrolling up to 120 patients at up to 20 U.S. sites in moderate-to-severely calcified femoropopliteal peripheral arterial disease, with expansion programs in coronary (first FIH enrollment May 2026) and carotid indications via a partnership with the Jacobs Institute. As of acquisition, Pulse IVL was investigational and not approved for commercial use in any geography; the planned revenue model combined low-capital console/amplifier placements (powered by a standard hospital Type E CO2 tank) with recurring single-use disposable balloon catheter sales to U.S. hospitals and interventional cardiology/vascular surgery departments.
On May 7, 2026, Stryker Corporation (NYSE:SYK) completed the acquisition of AVS for up to $835 million — a pre-FDA exit valuing the platform ahead of U.S. commercialization. Post-acquisition, the Pulse IVL System is distributed through Stryker's global peripheral vascular sales organization, with indications expanding from peripheral into coronary and carotid beds. AVS had raised approximately $64.8 million in cumulative venture funding (BioStar Capital-led across multiple Series B tranches between 2023 and 2025) plus early non-dilutive grant support from NIH/Cleveland Clinic and the University of Michigan's Fast Forward Medical Innovation program.
Amplitude Vascular Systems firmographics
Firmographics- Name
- Amplitude Vascular Systems
- Legal name
- Amplitude Vascular Systems, Inc.
- Website
- https://avspulse.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Amplitude Vascular Systems is a pre-commercial medical device company developing the Pulse IVL hydraulic intravascular lithotripsy system to fracture arterial calcium in peripheral, coronary, and carotid vessels for hospitals and interventional cardiologists; acquired by Stryker in May 2026 for up to $835 million.
- Ownership category
- akta.pro rank
Amplitude Vascular Systems industry classification
Industry- Product category
- Intravascular Lithotripsy Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Measuring, Dispensing, and Other Pumping Equipment Manufacturing (333914)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE)
- akta.pro secondary industries
- Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems) (HLAHAFAK), Vascular Medicine (Peripheral Arterial/Venous Disease) (HLAKABAG)
Keywords
Where Amplitude Vascular Systems is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Amplitude Vascular Systems business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Pulse IVL System hardware sales (planned): Investigational-device company; the Pulse IVL System is not yet approved for commercial use in any geography, so revenue had not begun prior to the May 2026 acquisition by Stryker. The planned model is capital equipment plus single-use disposable catheter sales (console + balloon catheter + amplifier + handle) to hospitals and interventional cardiology/vascular surgery departments.
- Post-acquisition revenue via Stryker: Following the May 2026 acquisition by Stryker (NYSE:SYK), revenue from the Pulse IVL platform is consolidated into Stryker's peripheral vascular portfolio and distributed through Stryker's global sales organization; financial terms of the deal were not publicly disclosed at close (separate reporting cited an up-to-$835 million deal value).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | Not publicly disclosed (investigational device) |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Amplitude Vascular Systems product offering
Product offeringCore offering
Amplitude Vascular Systems develops the Pulse IVL™ System, an investigational hydraulic intravascular lithotripsy (IVL) platform for treating severely calcified arterial disease. The system comprises a CO2-powered console, a single-button handle and amplifier, and a single-use non-compliant balloon catheter that delivers 15 uniform pulsatile pressure waves per second to fracture intimal and medial calcium and post-dilate the vessel. It is being clinically evaluated for peripheral, coronary, and carotid indications via the POWER PAD I first-in-human study and the FDA-approved POWER PAD II U.S. pivotal IDE trial.
Product overview
Amplitude Vascular Systems (AVS) offers a single, unified investigational medical device platform — the Pulse IVL™ System — together with the clinical evidence programs that support it. The Pulse IVL System is a hydraulic intravascular lithotripsy (IVL) platform composed of five integrated modules: the Pulse IVL Console (CO2-powered generator mounted on an IV pole), the Handle and Amplifier (single-button activator that converts pressurized CO2 into pulsatile energy), and the single-use Catheter and non-compliant Balloon (0.014" guidewire-compatible, delivering 15 uniform pulses per second at ~50 atm peak pressure to fracture intimal and medial calcium). Around this device, AVS runs the POWER PAD I first-in-human clinical study and the POWER PAD II U.S. pivotal IDE trial in peripheral arteries, with planned extensions into coronary and carotid indications via a strategic partnership with the Jacobs Institute. The platform targets severely calcified peripheral arterial disease as a next-generation, emitter-free alternative to electric wired balloons and lasers, and is being developed for U.S. FDA clearance and commercial launch following Stryker's 2026 acquisition of AVS.
Differentiator
Problem solved
Functional benefit
Brands
- Pulse IVL: The company's proprietary intravascular lithotripsy (IVL) system / platform for treating severely calcified arterial disease, using high-frequency hydraulic pulsatile pressure waves generated from pressurized CO2.
- PULSE IVL System
Products and services
- Pulse IVL™ System Investigational hydraulic intravascular lithotripsy (IVL) platform for treating severely calcified arterial disease. The system consists of a compact IV-pole-mounted console powered by a standard hospital Type E CO2 tank, a single-button reusable handle and amplifier that converts pressurized CO2 into hydraulic pulsatile energy waves, and a single-use 0.014" guidewire-compatible catheter with a non-compliant low-profile balloon that delivers ~50 atm peak pressure pulses at 15 pulses/second to uniformly and multi-directionally fracture intimal and medial calcium while post-dilating the vessel. It is intended for use by interventional cardiologists and vascular surgeons at hospitals to treat severely calcified peripheral arterial disease, with extension programs into coronary and carotid indications.
Quantifiable outcome
- POWER PAD I first-in-human study: 9 patients, 20 lesions (95% heavily calcified by PARC), 0 ≥ Grade D dissections, post-procedure stenosis reduced from 77%±18% to 21%±6%, acute luminal gain 3.0mm±0.9mm.
- +2 more outcomes
Companies that use Amplitude Vascular Systems
Customer profileSegments3 records
Ideal customer profiles3 records
Amplitude Vascular Systems technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Amplitude Vascular Systems partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- The Jacobs InstitutecoreStrategic agreement (announced August 2024) with the Jacobs Institute, a nonprofit medical device innovation center in Buffalo, NY led by Dr. Adnan Siddiqui, to expedite clinical trials for the Pulse IVL platform in coronary and carotid indications. Co-development collaboration to accelerate clinical evidence generation in non-peripheral vascular beds.
Scale indicators10 records
Recent moves8 records
Expansion highlights7 records
Amplitude Vascular Systems competitors and assessment
Company assessmentBroad incumbents
- Abbott Vascular: Large interventional cardiology and endovascular incumbent with deep peripheral and coronary portfolios (e.g., XIENCE stents, directional atherectomy). Competes with AVS as a broad incumbent treating the same calcified-artery patient population.
- Boston Scientific: Major interventional cardiology and peripheral vascular incumbent with broad atherectomy, stenting, and IVL portfolios (including the AVVIGO+ IVL system). Competes with AVS in treating calcified peripheral and coronary lesions as part of a much wider device lineup.
- Terumo Interventional Systems: Major peripheral and interventional cardiology device incumbent offering stents, balloons, and atherectomy tools. Comparable to AVS as a broad incumbent competing in calcified peripheral and coronary vessel preparation.
- Medtronic: Global interventional cardiology and peripheral vascular incumbent offering drug-coated balloons, stents, and atherectomy. Comparable to AVS as a multi-product incumbent in the calcified peripheral and coronary artery treatment markets.
- Philips (Intact Vascular): Acquired Intact Vascular (Tack dissection repair system) and competes broadly in interventional imaging and vascular intervention. Comparable to AVS as a broad incumbent and adjacent player in the peripheral vascular treatment space.
Emerging players
- Penumbra: Vascular thrombectomy and embolization device company that has expanded into peripheral and coronary interventions including mechanical circulatory support. Comparable to AVS as an emerging interventional vascular player pursuing adjacent peripheral and coronary indications.
- Silk Road Medical: Developer of the TCAR (transcarotid artery revascularization) system for carotid artery disease. Comparable to AVS as a focused endovascular company with carotid indications that could overlap with AVS's planned carotid IVL expansion.
- Avinger: Developer of image-guided atherectomy catheters (e.g., Pantheris, Ocelot) for peripheral arterial disease. Comparable to AVS as a smaller endovascular device company pursuing the same calcified peripheral lesion treatment opportunity.
Direct peers
- Cardiovascular Systems (CSI / Abbott): Orbital atherectomy device company (acquired by Abbott) that addresses severely calcified peripheral and coronary lesions. Directly comparable to AVS in that it offers an alternative vessel-preparation strategy to IVL for the same heavily calcified patient population.
- Shockwave Medical (Johnson & Johnson): Pioneer and dominant commercial player in intravascular lithotripsy for calcified peripheral and coronary artery disease. Acquired by J&J for ~$13B in 2024. Directly competes with AVS Pulse IVL in the same IVL category targeting calcified arterial lesions.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Amplitude Vascular Systems social profiles
Digital presenceAmplitude Vascular Systems financial estimates
Financial estimateRevenue estimate
Valuation estimate
Amplitude Vascular Systems leadership team
Management profileNumber of profiles
Profiles8 records
Amplitude Vascular Systems funding detail
Funding detailFunding overview
Funding rounds5 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Amplitude Vascular Systems M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Amplitude Vascular Systems
What does Amplitude Vascular Systems do?
Amplitude Vascular Systems develops the Pulse IVL™ System, an investigational hydraulic intravascular lithotripsy (IVL) platform for treating severely calcified arterial disease. The system comprises a CO2-powered console, a single-button handle and amplifier, and a single-use non-compliant balloon catheter that delivers 15 uniform pulsatile pressure waves per second to fracture intimal and medial calcium and post-dilate the vessel. It is being clinically evaluated for peripheral, coronary, and carotid indications via the POWER PAD I first-in-human study and the FDA-approved POWER PAD II U.S. pivotal IDE trial.
Is Amplitude Vascular Systems a public or private company?
Amplitude Vascular Systems is a private company. It is classified as corporate owned and is currently acquired.
When was Amplitude Vascular Systems founded?
Amplitude Vascular Systems was founded in 2017. It employs 11 to 50 people.
Where is Amplitude Vascular Systems based?
Amplitude Vascular Systems is headquartered in Boston, United States, in the North America region.
How does Amplitude Vascular Systems make money?
Two revenue lines are on record. Pulse IVL System hardware sales (planned) is the primary driver. The others are post-acquisition revenue via Stryker.
Who are Amplitude Vascular Systems's main competitors?
Broad incumbents on record are Abbott Vascular, Boston Scientific, Terumo Interventional Systems, Medtronic and Philips (Intact Vascular). Emerging players are Penumbra, Silk Road Medical and Avinger. Direct peers are Cardiovascular Systems (CSI / Abbott) and Shockwave Medical (Johnson & Johnson).
Does Amplitude Vascular Systems have an API?
No public API is recorded for Amplitude Vascular Systems.
What industry is Amplitude Vascular Systems in?
Amplitude Vascular Systems's product category is Intravascular Lithotripsy Medical Devices. Its primary akta.pro industry code is HLAHAFAE, Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy), with a secondary code of HLAHAFAK, Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems). Its NAICS code is 334510 and its SIC code is 3841.